

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029245 A1

- (51) International Patent Classification⁷: C12N 15/10, 15/62, 15/64, C07K 7/06, 7/08 (74) Agent: OY JALO ANT-WUORINEN AB; Iso Roobertinkatu 4-6 A, FIN-00120 HELSINKI (FI).
- (21) International Application Number: PCT/FI2003/000705 (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 29 September 2003 (29.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 20021726 27 September 2002 (27.09.2002) FI (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): CTT CANCER TARGETING TECHNOLOGIES OY [FI/FI]; Viikinkaari 4 C, FIN-00790 HELSINKI (FI).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VALTANEN, Heli [FI/FI]; Massbyntie 96/6, FIN-01150 SÖDERKULLA (FI). BJÖRKLUND, Mikael [FI/FI]; Ulvilantie 29/1 D 36, FIN-00350 HELSINKI (FI). KOIVUNEN, Erkki [FI/FI]; Lökkisaarentie 5 C 319, FIN-00980 HELSINKI (FI).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR DESIGNING PEPTIDES

(57) Abstract: The present invention relates to genetic engineering and, in specific, to design, generation, and modification of recombinant peptides using a combination of phage display and intein-mediated protein cleavage reaction.

WO 2004/029245 A1

Method for designing peptides

Field of the Invention

- 5 The present invention relates to genetic engineering and, in specific, to design, generation and modification of recombinant peptides using a combination of phage display and intein-mediated protein cleavage reaction.

Background of the Invention

10

Phage display and other high throughput screening methods have been used to obtain small molecular weight peptides that bind to selected receptors or other targets. Although peptides that bind to a target can be identified quite rapidly by biopanning, development of these sequences into useful high affinity peptides can take a substantial amount of time.

- 15 Furthermore, combinatorial methods such as phage display usually identify peptides based on binding interaction alone and thus finding of a biologically active peptide with sufficient water solubility may require testing of several candidates. Unfortunately, the preparation of a series of different peptides by chemical synthesis becomes laborious and expensive, especially when the peptides need to be cyclized using specific disulfide bond arrangements.
- 20

- To accelerate the identification of peptides with desired activity, peptides have been produced as fusion proteins with glutathione-S-transferase or alkaline phosphatase. However, a peptide may lose its activity when fused to a carrier protein. Furthermore,
- 25 when the peptide is an enzyme inhibitor, a fusion protein may not be well suited for the demonstration of such an activity. These problems can be avoided by releasing the peptide from the carrier using proteases, or peptide-bond hydrolysing chemicals such as cyanogen bromide or hydroxylamine, but the peptide yield is often very low. The use of these agents may also result in the degradation of the peptide itself.

30

Peptides found by phage display system may also be quite insoluble in water, which makes them difficult to study and use in biological systems.

An intein-mediated protein splicing system has been described for the preparation of recombinant proteins (Chong *et al.*, 1997). Inteins are proteins harboring protein-splicing activity and are commonly utilized as fusion partners to express recombinant proteins in bacteria. The self-cleaving ability of the intein allows the separation of the target protein from the intein so that no treatment with proteinase or peptide-bond-hydrolysing chemical is required (Chong *et al.*, 1997; Mathys *et al.*, 1999).

The splicing activity of inteins is inducible with e.g. thiol reagents or, on the other hand, with temperature and pH changes (Evans *et al.*, 1999).

10

Intein system has been applied to producing small cyclic peptides (WO 00/36093). The methods disclosed therein utilize the trans-splicing ability of split inteins to catalyze cyclization of peptides. The peptides produced in said publication are backbone-cyclic peptides, i.e. those having a peptide bond between the N- and C-terminal amino acids. In the method a target peptide is interposed between two portions of a split intein, which structure is essential for obtaining backbone-cyclized peptides.

While phage display is a powerful tool to select novel peptide ligands, current phage display libraries have a limited chemical diversity, as they must rely on the use of the twenty naturally occurring amino acids. There have been a few *in vitro* and *in vivo* approaches to add additional amino acids into phage displayed peptides and proteins. Also synthetic peptides with unnatural amino acids have been ligated to a phage-displayed protein that has been modified via phage-display mutagenesis (Dwyer *et al.*, 2000).

The incorporation of amino acid analogues to increase the chemical diversity of the phage display peptides is highly important as it could lead to the identification of more active and stable peptides that could better serve as lead compounds for the drug discovery process.

Summary of the Invention

30

We have now designed improved methods for peptide production and modification by exploiting the intein-mediated protein splicing as a method to rapidly produce phage display peptides in a soluble form. The methods of the invention are particularly useful in producing peptides having disulfide bridges, the peptide cleavage being carried out using

temperature/pH-inducible intein splicing. As an example the production of the dodecapeptide inhibitor of gelatinases CTTHWGFTLC (CTT) is described. CTT is a disulfide bond-containing low molecular weight peptide that has been discovered by screening random peptide libraries displayed on filamentous phage.

5

The intein system also allowed us to prepare CTT peptide variants, which contain unnatural amino acids. The CTT peptide containing 5-fluorotryptophan turned out to be more stable in human serum and a more potent inhibitor of tumor cell invasion than the wild type CTT peptide.

10

CTT-peptide is soluble in water. However, for labelling purposes it would be necessary to insert an additional tyrosine residue in the peptide. A chemically synthesized, modified CTT peptide with such additional tyrosine was, however, insoluble in water and made the peptide impractical to be used in laboratory. Consequently, we expressed a combinatorial library of CTT peptide containing an additional tyrosine flanked by random hydrophobic amino acids as an intein fusion, and tested the resulting peptides for solubility and activity. We found that using this system, peptides with improved solubility properties can be conveniently screened.

20 We thus used intein-mediated protein cleavage reaction for the generation of recombinant peptides in *E. coli*. The method allowed rapid production and purification of the ten-residue long gelatinase inhibitor peptide CTTHWGFTLC in milligram quantities. Alanine scanning mutagenesis of the peptide showed that the tryptophan residue is central for the gelatinase inhibitory activity. Intein cleavage also occurred after biosynthetic incorporation of hydroxylated and fluorinated tryptophan analogues into the intein fusion protein. The analogues were incorporated efficiently using a protein expression strain converted to a tryptophan auxotroph by insertional mutagenesis using *in vitro* assembled bacteriophage Mu DNA transposition complexes. All tryptophan analogue-containing peptides retained the gelatinase inhibitory activity. 5-fluorotryptophan-containing peptide showed enhanced stability in serum and was more potent inhibitor of tumor cell invasion than the wild type CTTHWGFTLC peptide. These studies open new possibilities to modify peptides and improve their activity by biosynthetic incorporation of unnatural amino acids. Collectively these studies show that intein-mediated expression of peptides is a versatile tool for peptide

30

design and may enable development of highly active peptides with potential therapeutic applications.

Furthermore, we performed phage selection using proMMP-9 as a target. After three
5 rounds of selection, we cloned the resulting peptides in an intein vector using a pair of
oligonucleotide primers that were designed so that any phage peptide insert can be
amplified without the knowledge of the peptide sequence. The resulting peptides have a
sequence ADGA-(X)_n-GAAG, where the ADGA and GAAG amino acid sequences are
derived from the phage and (X)_n is the peptide insertion. As an example, two such peptides
10 were successfully expressed and their specificity could be shown by inhibition of phage
binding.

In addition, a peptide display system is described, where an auxotrophic *E. coli* is used for
the incorporation of amino acid analogues into phage particles. This system may facilitate
15 selection of peptides with improved activity or stability. In an auxotrophic bacterial strain
the amino acid auxotrophism enforces the misaminoacylation of transfer RNAs in the
absence of the naturally occurring amino acid with subsequent incorporation of the amino
acid analogues into polypeptides. Said method is used herein for the production of phage
particles.

20 Consequently, the present invention is generally directed to a method for producing a
peptide, comprising the steps of providing a nucleic acid molecule encoding a polypeptide
comprising a peptide of interest, incorporating said nucleic acid molecule into an
expression vector as a fusion with an intein, and expressing the peptide-intein-fusion.

25 In a preferred embodiment of the invention the nucleic acid molecule provided for the
method is a PCR-amplified nucleic acid molecule originating from a phage display vector
or, alternatively, from ribosome display, plasmid-peptide display or another genetic display
system.

30 As further steps the method may comprise a step of induction of the peptide cleavage, and
purification of the peptide by an affinity column. In a preferred embodiment of the
invention the induction of the peptide cleavage is carried out by temperature and pH
change.

The method is usually carried out *in vivo* using a suitable host system. In such a system the peptide-intein-fusion is expressed in e.g. *Escherichia coli* cells. Other microbial or eukaryotic hosts, such as yeast cells, insect cells and mammalian cells can be used as well.

5

On the other hand, the method can also be carried out *in vitro*. In such a method the translation is done without live cells and the translation machinery is obtained usually from cell lysate or an extract of cells.

- 10 The method as generally described above can be applied for a variety of purposes in peptide design, for instance for constructing a library of peptides with random hydrophilic amino acids to improve the water solubility of the peptides, for producing peptides with unnatural amino acids, or for producing a pool of peptides to be screened for improved properties.

15

A specific application of the method is production of any peptide obtained by phage display, in which case a pair of universal intein oligonucleotide primers are designed, whose structures enable amplification of a peptide insert without the knowledge of the peptide sequence.

20

We thus designed the following universal primers.

(1) Intein Fwd *SapI* primer having the sequence: CCT TTC TGC TCT TCC AAC GCC GAC GGG GCT. This primer will add amino acids ADGA from the phage to the peptide.

(2) Intein Rev *PstI* primer having the sequence: ACT TTC AAC CTG CAG TTA CCC

- 25 AGC GGC CCC. This primer will add amino acids GAAG from the phage to the peptide.

These primer sequences can be used to amplify and clone any phage display peptide as an intein fusion. Briefly, the phage peptides are amplified using PCR and the inserts digested with *SapI* and *PstI* restriction enzymes. The peptide inserts are ligated to similarly digested
30 intein vectors. The ligated vectors are transformed into host cells, and expressed. As a further step the method may comprise the step of purifying the peptides obtained from the host cells.

Our studies extend the utility of intein system to the production of small molecular weight peptides and their modification with unnatural amino acids. The possibility to incorporate unnatural amino acids such as fluorinated tryptophan should facilitate development of peptides with enhanced activity and/or stability to be used further in the drug discovery process. Furthermore, by using modified strains with multiple amino acid auxotrophies, one could replace several amino acids with unnatural ones.

In a preferred embodiment for preparing a peptide containing an unnatural amino acid, such a peptide is directly selected using phage display in an auxotrophic host and, subsequently, the selected peptide is expressed as an intein fusion on a phage.

This unnatural amino acid display system is fully compatible with the existing phage libraries made into fUSE5 vector, as the incorporation of the amino acid analogues is independent of specific codons. Thus, new libraries containing amino acid analogues can be simply generated through infection with the existing libraries. This circumvents the tedious cloning and transformation step needed for library making. Furthermore, the intein-assisted peptide expression efficiently complements the phage display system, e.g., the fluorotryptophan-containing peptides can be directly expressed as soluble peptides for activity analysis.

This system may work best with the rare amino acids such as tryptophan. The ability to incorporate tryptophan analogues into phage libraries is important because tryptophan is very often enriched in the peptides selected by phage display.

Detailed Description of the Invention

Abbreviations:

CTT:	CTTHWGFTLC peptide (Koivunen <i>et al.</i> , 1999a)
iCTT:	recombinant CTTHWGFTLC peptide;
STT:	STTHWGFTLS peptide;
MMP:	matrix metalloproteinase;
5OH-Trp:	5-hydroxytryptophan;
5F-Trp:	5-fluorotryptophan;
6F-Trp:	6-fluorotryptophan;
7A-Trp:	7-azatryptophan.

Description of the Figures

Figure 1A and 1B. Inhibition of MMP-2 and MMP-9 by synthetic or intein-produced peptides. (A) MMP-9 was treated with CTT, iCTT, or STT at the peptide concentrations indicated. MMP-9 activity was determined using biotinylated gelatin. (B) The activity of the alanine mutant peptides (see Table 1) was compared to that of CTT, which inhibited MMP-2 by 100% in the gelatin degradation assay. In all assays the peptides were preincubated with the enzyme for 30 min before the substrate was added. The results show means \pm SD from triplicate measurements and are representative from at least two independent experiments.

Figure 2A, 2B, 2C and 2D. Incorporation of the tryptophan analogues in the intein-CTT peptide fusion protein. (A) Tryptophan analogues used in this study (B) 12% SDS-PAGE showing the urea solubilized bacterial lysates of intein-CTT fusions. All samples were induced with IPTG. The apparent molecular weight of the intein-CTT fusion is about 30 kDa. (C) Ultraviolet absorption spectra of normal tryptophan and 5OH-Trp containing CTT peptides. The absorbance spectra of the 5F-Trp and 6F-Trp containing peptides are similar to that of the wild type peptide and are not shown. (D) Fluorescence emission spectra of the CTT peptides containing tryptophan analogues. The fluorescence emission maxima of the peptides were normalized to the same value.

Figure 3A and 3B. Activity and stability of the tryptophan analogue containing CTT peptides. (A) Inhibition of MMP-2 using β -casein (21 kDa) as substrate. The peptides (100 μ M) were incubated with MMP-2 and β -casein (0.1 mg/ml) for 2 h and samples run on a 15% SDS-PAGE gel. (B) iCTT, 5F-CTT or a negative control peptide CERGLETSC at a 150 μ M concentration was incubated in undiluted human serum for the indicated time periods at 37°C. Samples were withdrawn, stored frozen and blotted on a nitrocellulose membrane. The level of CTT was quantitated using polyclonal anti-CTT antibody. The blots were scanned and the results shown are means \pm SD from triplicate measurements. The results were similar in two other experiments.

Figure 4A and 4B. Peptide inhibition of HT-1080 tumor cell invasion examined in 10% heat-inactivated fetal calf serum (A) or 10% non-heated normal human serum (B). The cells were allowed to migrate through the Matrigel-coated Transwells for 16 h in the absence or presence of the recombinant peptides at a 150 μ M concentration. The results show means \pm SD from triplicate wells. The results are representative from three independent experiments. An asterisk (*) indicates statistically significant difference ($p < 0.05$) in Student's t-test.

Figure 5. Inhibition of gelatinase A (MMP-2) with CTT-peptide, with pool 1 and pool 2, both containing 10 different peptide derivatives of CTT. The library contains 216 different combinations of CTT peptide derivatives. Clone 4 from pool 1 and clone 7 from pool 2 were purified and tested also for their inhibition activity against gelatinase A.

Figure 6. A peptide insert from a phage clone #43 specifically binding to proMMP-9 was cloned with the universal intein oligonucleotide primers and the intein-peptide fusion was expressed and the peptide purified with HPLC. Microtiter wells were coated with 20 ng/well proMMP-9, blocked with bovine serum albumin, and the phages were allowed to bind in the presence or absence of 15 μ M peptides. Unbound phages were washed with TBS-Tween and bound phage detected with anti-phage antibody-HRP conjugate. The expressed and purified peptide #43 inhibited binding of phage bearing the same peptide #43 to proMMP-9, but not the binding of another proMMP-9-binding phage bearing a different peptide (peptide #63). Similarly, peptide insert #63 inhibited only the binding of the phage bearing peptide #63 but not the phage bearing peptide #43. The peptide CTT had no effect on the binding of phages #43 and #63, confirming the specificity of the phage binding.

Figure 7. Schematic representation of the strategy to prepare the auxotrophic phage host strains.

Figure 8. Structures of the amino acid analogues tested for phage incorporation.

Figure 9A and 9B. Phage production in the presence of the amino acid analogues. The phages were prepared as described in the methods. Serial dilutions of the culture supernatants were made in triplicate and these were used to infect *E. coli* K91/kan. The

percentage of infective phage compared to phage culture in the presence of the parental amino acid is shown. Representative data from the phage production in the presence of tryptophan (A) and methionine (B) analogues are shown.

- 5 **Figure 10.** Fluorotryptophan incorporation changes the intrinsic fluorescence properties of phages. The phage samples were denaturated by heating in 1% SDS containing buffer and the fluorescence spectra recorded were recorded with an excitation at 295 nm. Fluorescence emission was measured in the range of 300-500 nm.
- 10 **Figure 11.** Enrichment of fluorophage library after two rounds of biopanning with human cell lines Eahy926 and KS1767. The phages were subtracted with Eahy926 cells and selected for KS1767 binding.

Experimental

15

Methods

- Chemical peptide synthesis.** Peptides were synthesized with an Applied Biosystems model 433A (Foster City, CA) using Fmoc-chemistry as reported previously (Koivunen *et al.*, 1999a), except that disulfide bond formation was done using hydrogen peroxide. Briefly, the peptide was dissolved in 50 mM ammonium acetate (pH 7.5) at a 1 mg/ml concentration and 0.5 ml of 3 % hydrogen peroxide per 100 mg peptide was added. After 30 min incubation, pH was adjusted to 3.0 and the cyclized peptide was purified by reverse-phase HPLC using a linear acetonitrile gradient (0%→70% during 30 min) in 0.1% trifluoroacetic acid.
- 20
- 25

- Cloning of the intein-peptide fusions.** A synthetic oligonucleotide 5'-GGTGGTG-CTCTTCCAAGTACGACCCATTGGGGATTACTTTATGTAACTGCAGGCG-3' encoding the CTTHWGFTLC peptide was converted to double stranded form using Dynazyme II DNA polymerase (Finnzymes, Espoo, Finland) with a primer 5'-CGCCTG-CAGTTAACA-3', and digested with *SapI* and *PstI*. Purified insert was ligated in frame to *SapI*-*PstI*-digested pTwin vector backbone (New England Biolabs) (Evans *et al.*, 1999). The presence of the correct insert was verified by sequence analysis. Similar cloning strategy was used to prepare the alanine-mutant peptides using codon GCG for alanine. For
- 30

the cloning of any phage peptide inserts, universal oligonucleotides 5'-CCT TTC TGC TCT TCC AAC GCC GAC GGG GCT-3' (Intein Fwd *SapI*), 5'-ACT TTC AAC CTG CAG TTA CCC AGC GGC CCC-3' (Intein Rev *PstI*) were used. For the hydrophilic CTT peptide library, a synthetic degenerate oligonucleotide 5'-GGTGGTTGCTCTTCCAACG-
5 GCGGCCVAVVAVTATVAVGGCTGTACCACCCATTTACTTTATGTAACTGCAG-GCG-3' (where V is A, C or G) was prepared, and converted to double-stranded DNA with the same primer as the normal CTT peptide.

Peptide production in bacteria. The plasmids encoding intein fusion peptides were
10 transformed into *E. coli* ER2566 strain (New England Biolabs). The clones were cultured in LB medium containing 100 µg/ml ampicillin until OD₆₀₀ was 0.7. The protein expression was induced with 0.3 mM IPTG and incubation continued for 4 h at 37°C. The bacterial pellets were suspended in 20 mM Tris-HCl (pH 8.5) / 500 mM NaCl / 1 mM EDTA / 1% Triton X-100 (Buffer B1). Following sonication and centrifugation, the
15 soluble fraction was applied on a chitin affinity column (New England Biolabs). The insoluble fraction containing most of the intein-fusion protein was solubilized with 8 M urea / 100 mM Tris-HCl (pH 8.0) / 100 mM NaCl / 2 mM EDTA and sonicated. The solubilized material was subsequently diluted at least 1:16 with the buffer B1 without Triton X-100 and cleared by centrifugation. The clarified supernatant was also applied on
20 the chitin column. The column was washed extensively with buffer B1 lacking Triton X-100. The intein-cleavage reaction was performed on-column by overnight incubation in 50 mM ammonium acetate / 1 mM EDTA (pH 7.0) at 22°C. The free peptide was eluted, concentrated by lyophilization or by Sep-Pak C18 cartridges (Waters) and purified with reverse-phase HPLC. The identity of each peptide was verified by MALDI-TOF mass
25 spectrometry. Peptides were quantified using o-phthalaldehyde or HPLC analysis. Known concentrations of the CTT peptide were used as standards.

Generation of tryptophan auxotrophic *E. coli* ER2566 mutant. *In vitro* assembled bacteriophage Mu DNA transposition complexes were prepared essentially as described
30 previously (Lamberg *et al.*, 2002). Briefly, 1.1 pmol transposon DNA containing a kanamycin resistance gene and 4.9 pmol MuA protein were mixed in 20 µl of 150 mM Tris-HCl (pH 6.0) / 50% glycerol / 0.025% Triton X-100 / 150 mM NaCl / 0.1mM EDTA. The transposition complex assembly reaction was carried out at 30°C for 2 h. The complexes were electroporated as 1:8 or 1:16 dilutions into electrocompetent *E. coli*

ER2566 and plated on LB plates containing 50 µg/ml kanamycin. The clones obtained were replica-plated on M9 minimal plates and M9 plates containing 1 mM DL-tryptophan (Sigma). A clone named ER2566/Trp82 requiring Trp for growth was chosen for further studies. To determine the transposon insertion site, the chromosomal DNA was isolated with genomic DNA isolation kit (Qiagen) and digested with *Pst*I. The resulting genomic fragments were ligated with *Pst*I digested pUC19 plasmid and transformants selected in the presence of kanamycin. The DNA sequences of transposon borders were determined by sequencing with transposon specific primers 5'-ATCAGCGGCCGCGATCC-3' and 5'-TTATTCGGTCGAAAAGGATCC-3'. The genomic location of the insertion was identified using the BLAST search.

Generation of auxotrophic *E. coli* for amino acid analogue incorporation into phage particles. *In vitro* assembled bacteriophage Mu DNA transposition complexes containing a kanamycin resistance gene were prepared and electroporated into MC1061 as described previously (Lamberg *et al.*, 2002). Successful transpositions were identified by gain of kanamycin resistance and the resulting colonies were screened for auxotrophism by replica-plating on M9 minimal agar plates containing 0.5 mM L-leucine, 1mM thiamine in the absence or presence of 0.5 mM methionine or tryptophan. Clones requiring Met or Trp for growth were selected for the incorporation studies. To allow phage infection, F'-pilus [lacIq L8 pro with Tn9 in lacYZ] from the *E. coli* strain NK5468 (*E. coli* Genetic Center, Yale University, New Haven, CT) was transferred by mating. Successful matings were identified by the acquisition of a chloramphenicol resistance.

Incorporation of tryptophan analogues into peptides. The plasmid coding for intein-CTT fusion was transformed into the auxotrophic ER2566/Trp82. The clone was cultured in M9 medium supplemented with 0.6% glycerol, 0.1 mM CaCl₂, 2 mM MgCl₂, 0.01 mM FeSO₄, 100 µg/ml ampicillin, 25 µg/ml kanamycin and 0.5 mM DL-tryptophan until OD₆₀₀ reached 0.8-1.0. Incorporation of the tryptophan analogues 5-hydroxy-L-tryptophan (5OH-Trp, Sigma), 5-fluoro-DL-tryptophan (5F-Trp), 6-fluoro-DL-tryptophan (6F-Trp) and DL-7-azatryptophan (7A-Trp, ICN Biomedicals) was accomplished by a medium shift procedure (Minks *et al.*, 1999; Mohammadi *et al.*, 2001; Ross *et al.*, 1997; Tang *et al.*, 2001). The bacteria were centrifuged and suspended in fresh M9 medium lacking tryptophan or analogues. The bacteria were grown for 15 min at 37°C to exhaust most of remaining tryptophan, and the tryptophan analogue was then added at a 0.5 mM final

concentration together with 0.5 mM IPTG. After 4 h cultivation at 37°C, the bacteria were pelleted, and the fusion protein purification was done as above.

Gelatinase inhibition assays. Gelatinases proMMP-2 and proMMP-9 (Roche) were activated with p-aminophenylmercuric acetate or trypsin, respectively, and then incubated in the presence or absence of each peptide to be tested for 30 min. The gelatinase inhibitory activity was determined using the following three assays: (i) The degradation of biotinylated gelatin was examined using a gelatinase activity kit according to the manufacturer's instructions (Roche). (ii) The degradation of a MMP-2 specific fluorescent peptide substrate MCA-Pro-Leu-Ala-Nva-Dpa-Ala-Arg-NH₂ (Calbiochem) (2.5 μM final concentration) was followed using MOS-250 spectrofluorometer (Bio-Logic SA, Claix, France) with 330 nm excitation and 390 nm emission. (iii) The degradation of β-casein was studied by incubating activated MMP-2 with 0.1 mg/ml concentration of β-casein for 2 h at 37°C, after which the samples were analyzed on a 15% SDS-PAGE gel.

15

Cell invasion. HT-1080 human fibrosarcoma cells were cultured in DMEM medium containing 10% fetal calf serum and supplemented with penicillin, streptomycin and L-glutamine. Cell invasion assay was conducted using Matrigel coated invasion chambers in the serum-containing medium as described (Koivunen *et al.*, 1999a). Briefly, the cells were preincubated with the peptides for 1 h and then allowed to migrate through the Matrigel coated invasion chambers (Becton Dickinson) for 16 h. The migrated cells were stained with crystal violet and counted.

Spectrometry and fluorometry. The absorbance spectrum for each peptide in the 200-375 nm range was measured in 20 mM Tris-HCl (pH 7.4) / 50 mM NaCl / 0.1 mM EDTA with Genesys 5 spectrophotometer (Thermo Spectronic, Rochester, NY). The fluorescence spectra of the CTT phage cultured in the presence of tryptophan, 5FW or 6FW were measured from heat-denatured phages (2x10⁹/ml) in 10 mM Tris-HCl (pH 7.5) / 140 mM NaCl / 1% SDS. The fluorescence emission spectra (average of three scans) at 300-500 nm were recorded with MOS-250 spectrofluorometer. The peptides were excited at 295 nm (bandwidth 5 nm) and the emission spectra recorded in the 300-500 nm range.

Peptide stability in human serum. Blood samples were collected from the laboratory personnel and the sera stored in aliquots at -70°C. The peptides were added to the

undiluted human serum at the final concentration of 150 μ M. The serum was incubated at 37°C and aliquots were taken at different time points, diluted in PBS / 0.05% Tween 20, and immediately frozen in liquid nitrogen. The samples were thawed and loaded on a nitrocellulose membrane using a 96-well dot blotter. Following blocking with 5% BSA in TBS / 0.05% Tween 20, the membrane was incubated with a 1:500 dilution of anti-CTT rabbit serum which was prepared by immunizing with the CTT-peptide coupled to keyhole limpet hemocyanin (Sigma). Bound anti-CTT antibody was detected by enhanced chemiluminescence using peroxidase-conjugated anti-rabbit antibody (DAKO, Denmark), at a 1:2000 dilution.

10

Amino acid analogues. DL-ethionine (Eth), DL-norleucine (Nle), 4-aza-DL-leucine (Ale), 5-hydroxy-L-tryptophan (5OH), 5-fluoro-DL-tryptophan (5FW), 6-fluoro-DL-tryptophan (6FW), and DL-7-azatryptophan (7AW) were from Sigma-Aldrich or ICN Biomedicals.

15 **Incorporation of amino acid analogues into phage particles.** The filamentous bacteriophage fUSE5 displaying the CTT peptide was cultured in MB5F or MB64F strains in a chemically defined M9 medium supplemented with 0.2% glucose, 0.1 mM CaCl_2 , 2 mM MgCl_2 , 0.01 mM FeSO_4 , 20 μ g/ml tetracycline, 25 μ g/ml kanamycin, 10 μ g/ml chloramphenicol, 1 mM thiamine, 0.2 mM each of guanosine, uracil, adenine and thymidine, and all the twenty amino acids in a 0.1-0.8 mM concentration (Neidhardt *et al.*, 1974). Incorporation of the amino acid analogues was accomplished by a medium shift procedure. Briefly, the bacteria ($\text{OD}_{600} = 0.7-1.0$) were centrifuged and suspended in a fresh M9 medium lacking the amino acid to be replaced. The analogues were added at a 0.5-2 mM final concentration (as the L-isomer) and the bacteria were cultured overnight.

25

Phage quantitation. Serial dilutions of the phage supernatants were prepared and these were used to infect the *E. coli* K91/kan strain using standard techniques (Koivunen *et al.*, 1999b). Ten μ l aliquots of the infections were plated in triplicates on LB agar plates containing 40 μ g/ml tetracycline and 10 μ g/ml kanamycin. After an overnight incubation, the number of bacterial colonies was counted.

30

Preparation of a fluorophage library. 15 μ l aliquots of CX₇C, CX₈C and X₉C libraries (Koivunen *et al.*, 1999a, Koivunen *et al.*, 2001) were infected to MB5F strain cultured in Terrific Broth. The phage infection resulted in 0.5×10^9 individual clones. After an

overnight incubation, the bacteria were subcultured into one litre M9 medium and cultured overnight. The medium shift procedure was performed as above and the 5FW and 6FW analogues were added simultaneously to 0.5 mM final concentration. The next day resulting phage were precipitated twice with polyethylene glycol (PEG)/NaCl (Koivunen *et al.*, 1999b).

Biopanning with the fluorophage library. A total of 2.5×10^5 Eahy926 cells (Koivunen *et al.*, 1999a, Koivunen *et al.*, 2001) were suspended in 150 μ l 1% bovine serum albumin in DMEM medium and incubated with an aliquot of the fluorophage library (1×10^9 transducing units) for 4 h at +4°C. The cells were centrifuged through a bovine serum gradient (Williams *et al.*, 2002) and the resulting phage supernatant was applied to 2.5×10^5 KS1767 cells and incubated for 4 h at +4°C. The sample was centrifuged again through a serum gradient and the cell pellet was used to infect MB5F bacteria. The bacteria were grown overnight and then for another day in the presence of fluorotryptophans. The phage were collected and used for a second round of subtraction with Eahy926 cells and selection with KS1767 cells.

Results

20 Peptide biosynthesis using an intein vector

We chose the *Ssp DnaB* mini-intein with C-terminal cleavage activity for the peptide production, as this intein contains only 154 amino acids and the C-terminal protein fusions are typically efficiently expressed. Furthermore, the cleavage activity of this intein is induced by a pH and temperature change from pH 8.5 and 4°C to pH 7.0 and 22°C. We could thus avoid the thiol-induced intein cleavage, which might interfere with the disulfide bonding and the activity of a peptide. One of the advantages for using an intein for the production of peptides with cysteines in the termini is that cysteine is a catalytically favorable amino acid resulting in high cleavage efficiency (Paulus, 2000).

30 We began our studies by examining intein-mediated production of the ten-residue long gelatinase inhibitor peptide CTT, which is active only in the cyclic disulfide form. Essentially all intein-CTT fusion protein was found in inclusion bodies and was recovered by solubilization in urea. The peptide could be obtained in 70-90% purity after the on-column cleavage reaction. The yield after the final HPLC purification was up to 2 mg

peptide from one liter of bacterial culture. The intein-fusion derived CTT (iCTT) was spontaneously cyclized having the expected molecular weight of the disulfide bond-containing CTT peptide in mass spectrometry (Table 1). Next, alanine-scanning mutagenesis of CTT was carried out to identify amino acid residues required for the
 5 gelatinase inhibitory activity. The Ala-substituted peptides were obtained with similar yields as iCTT. Mass spectrometry confirmed the identity of each cyclic peptide (Table 1).

Table 1. Recombinant peptides prepared by the intein system.

10

Peptide	Sequence	Mass, Da	
		Calc. *	Obs.
iCTT	CTTHWGFTLC	1166.4	1166.5
T1→A	CATHWGFTLC	1136.3	1136.4
T2→A	CTAHWGFTLC	1136.3	1136.4
H→A	CTTAWGFTLC	1100.3	1100.5
W→A	CTTHAGFTLC	1051.2	1051.4
G→A	CTTHWAFTLC	1180.4	1180.5
F→A	CTTHWGATLC	1090.3	1090.4
T3→A	CTTHWGFALC	1136.3	1136.5
L→A	CTTHWGFTAC	1124.3	1124.4
5OH-CTT	CTTH(5OHW)GFTLC	1182.4	1182.4
5F-CTT	CTTH(5FW)GFTLC	1184.4	1184.3
6F- CTT	CTTH(6FW)GFTLC	1184.4	1184.2

*molecular weight calculated for the oxidized, cyclic form

Functional analysis of the gelatinase inhibitory peptides

15 The gelatinase inhibitory activity of iCTT was found to be identical with that of the chemically synthesized CTT in several assays. In gelatin degradation assay, iCTT and CTT exhibited a similar dose dependency, the IC₅₀ values being 20 μM for both MMP-2 and MMP-9 inhibition (Fig. 1A and data not shown). The non-cyclic synthetic control peptide STTHWGFTLS (STT) was several fold less active than iCTT.

Analysis of the Ala-substituted peptides in the gelatin degradation assay showed that changes of tryptophan, glycine and phenylalanine significantly decreased the gelatinase inhibitory activity (Fig. 1B). The W→A, G→A and F→A mutant peptides had 17±12, 53±7 and 36±7 % of the activity in comparison to the wild type peptide, respectively. Ala-replacements at all the other positions did not appreciably affect the gelatinase inhibitory activity. For example, the peptide with H→A substitution retained about 80% of the wild-type activity. Similar results were obtained by comparison of the peptides in the fluorogenic MMP-2 substrate assay (data not shown).

Biosynthesis of peptides containing tryptophan analogues

Having demonstrated the capability of the intein expression for peptide synthesis, we examined the possibility of incorporating unnatural amino acids into intein-derived peptides. We focused our studies on the modification of the single tryptophan residue of CTT as it seemed to offer the best possibilities to modulate the activity and possibly the stability of the peptide. A tryptophan auxotrophic *E. coli* required for efficient incorporation of unnatural tryptophan analogues was prepared by mutagenesis using *in vitro* assembled bacteriophage Mu DNA transposition complexes. A clone designated as ER2566/Trp82 was isolated and found to be auxotrophic for tryptophan. The transposon insertion site was in the genomic location duplicating the nucleotides 1315340-44, numbered according to completely sequenced *E. coli* K12 strain. Thus, the correct five base pair target site duplication characteristic to Mu transposition was identified (Lamberg *et al.*, 2002). The insertion was within the *trpB* gene encoding for tryptophan synthase β subunit, consistent with the observed phenotype.

The Er2566/Trp82 clone was used to express CTT intein fusion with 5-hydroxytryptophan, 5-fluorotryptophan, 6-fluorotryptophan or 7-azatryptophan added into the bacterial culture (Fig. 2A). Previously, these tryptophan analogues have been incorporated into several proteins synthesized by tryptophan auxotrophic *E. coli* (Minks *et al.*, 1999; Mohammadi *et al.*, 2001; Ross *et al.*, 1997). There are seven tryptophan residues in the expressed intein fusion protein, three in the chitin-binding domain, three in the intein and one in the CTT peptide. We observed incorporation of all four tryptophan analogues into the intein fusion protein (Fig. 2B). On SDS-PAGE, the intein-fusion protein containing fluorinated Trp

analogues migrated faster than the protein with normal tryptophan. The more polar 5OH-Trp and 7A-Trp residues on the other hand caused the fusion protein to migrate slower. The yields of the fusion proteins were slightly reduced (5OH-Trp, 5F-Trp and 6F-Trp) or significantly reduced (7A-Trp) as compared with the wild type protein. Notably, 5F-Trp and 6F-Trp did not significantly impair the intein cleavage activity and the CTT peptides containing fluorinated Trp were obtained at about 0.3 mg yield per liter minimal medium. The 5OH-Trp residue affected the intein cleavage causing reduced peptide yields. 7A-Trp containing peptide was not obtained in amounts sufficient for activity determination. Mass spectrometry confirmed that each peptide contained the expected unnatural tryptophan analogue (Table 1). Only a minor amount of wild type CTT peptide was present in fluorinated peptide preparations and no wild type peptide at all could be detected in the 5OH-CTT preparation (data not shown). The identity of the modified peptides could be further confirmed by ultraviolet absorption and fluorescence spectroscopy. The 5OH-Trp containing CTT peptide had a characteristic absorbance profile with a distinct red-shifted secondary absorption maximum (Fig. 2C). All modified peptides differed in their fluorescence emission spectra from the wild type peptide (Fig. 2D).

The gelatinase inhibitory activities of the modified CTT peptides were tested in the β -casein degradation assay (Fig. 3A) and the gelatin degradation assay (data not shown). No significant differences in the gelatinase inhibitory activity were seen in these assays. At a 100 μ M concentration 5OH-Trp, 5F-Trp and 6F-Trp containing peptides inhibited MMP-2 with a similar efficiency as iCTT does with nearly complete inhibition of casein degradation. As amino acid analogues can contribute to the protease sensitivity of the peptides, we next studied the stability of the peptides by incubating them in normal human serum. To determine the peptide levels, we used anti-CTT antibody that also recognized the 5F-Trp containing peptide. The 5F-Trp containing peptide was more stable in serum with a half-life of 3 hours in comparison to the 0.5 hour half-life of the wild type CTT peptide (Fig. 3B). We could not determine the half-lives of 5OH-Trp and 6F-Trp containing peptides as the anti-CTT antibody recognized these peptides only weakly in the presence of serum. The CTT antibody was highly specific as cyclic control peptides CERGGLETSC and CPCFLLGCC did not react with the anti-CTT antibody. No difference between the stability of CTT and 5F-Trp containing peptide was seen in cell culture medium supplemented with 10% heat-inactivated fetal calf serum (data not shown).

In the cell invasion assay, the 5F-Trp and 6F-Trp containing peptides displayed an activity similar to that of iCTT when the cells were cultured in the presence of 10% heat-inactivated fetal calf serum (Fig. 4A). However, when the HT-1080 cells were cultured in 10% human serum that had not been heat-inactivated, the 5F-Trp containing peptide was significantly better inhibitor of cell invasion than iCTT (Fig. 4B), correlating with the serum stability data. This effect was specific for fluorine substitution at 5-position of Trp as the activity of the 6F-Trp containing peptide did not differ from that of the wild type peptide.

10 Preparing a hydrophilic intein peptide library

To achieve labeling of the CTT peptide with radioactive iodine, peptides with additional tyrosine were prepared by chemical synthesis. However, these peptides were found insoluble in water, although the CTT peptide itself is water-soluble. Thus, we prepared a peptide library with intein system to screen for a water-soluble tyrosine-containing CTT peptide. A degenerate oligonucleotide having randomized amino acids coding for polar amino acids were used to potentially enhance the solubility of the tyrosine containing CTT peptide. The resulting library coded for peptides GRXXYXGCTTHWGFTLC, wherein X is any hydrophilic amino acid. First an oligonucleotide 5'-GGTGGTTGCTCTTCCAACG-GCCGCCVAVVAVTATVAVGGCTGTACCACCCATTTACTTTATGTTAACTGCAG-GCG-3' was designed, and prepared by combinatorial synthesis using an oligonucleotide synthesizer. The oligonucleotide contained three VAV codons, (wherein V is G or A or C), which code for hydrophilic amino acids.

The oligonucleotide was made double-stranded using PCR. The PCR product was digested with *Pst*I and *Sap*I and cloned to TWIN2 intein vector (New England Biolabs), digested also with *Pst*I and *Sap*I. This DNA construct was electroporated into MC1061 competent cells. The library obtained contained 216 variations of the CTT-peptide. The plasmid vectors were extracted from the pool of at least 216 independent clones of MC1061. The plasmids were then electroporated to ER2566 cells enabling the production of inteins. The cells harboring the plasmids were plated on LB plates containing ampicillin. 10 independent clones were pooled to one single pool. These 10 clones in one pool were cultured and the peptides were expressed and purified with chitin affinity column and reverse-phase C18 column. Each pool of peptides was tested for activity. The solubility in

PBS was also tested. Two clones of two pools with distinct activity and good solubility were cultured, and the peptides were purified as described above. One of these peptides (having the sequence GRENHYHGCTTHWGFTLC) was more soluble into water or PBS than the original peptide, and it was active (Figure 5). The plasmid coding for this peptide was sequenced and the peptide was synthesized with chemical synthesis.

To demonstrate the utility of the general strategy to express any phage display peptide as an intein fusion, universal primers were used to amplify peptides from phages selected for binding to proMMP-9. The peptide inserts from phage clones specifically binding to proMMP-9 after three rounds of phage selection were amplified and cloned into an intein vector. The peptides were expressed, and purified with HPLC. The specificity of the phage binding to proMMP-9 and the identity of the peptides was confirmed by phage ELISA. The peptides expressed by the intein system only blocked the binding of phage with the same peptide insert, but did not compete with the binding of phage bearing another insert (Figure 6).

Incorporating amino acid analogues into phage particles

To achieve a high-level phage production together with efficient incorporation of the amino acid analogues, we mutagenized the *E. coli* strain MC1061 commonly used for the preparation of phage display libraries. Auxotrophic derivatives for tryptophan and methionine were isolated by random insertional mutagenesis using *in vitro* assembled bacteriophage Mu DNA transposition complexes according to Lambert *et al.* 2002. The parental strain MC1061 does not have the F pilus required for the phage infectivity, thus we transferred the F' pilus from the *E. coli* strain NK5468 to the newly isolated auxotrophic strains. This resulted in the tryptophan auxotroph strain designated MB5F and the methionine auxotroph MB64F. Fig. (7) illustrates the strategy to obtain the bacterial strains for the peptide display system. The new strains were functional as they could be infected with the filamentous phage, although the infectivity was about 10% compared to the K91/kan host.

30

The commercially available tryptophan analogues 5-hydroxy-L-tryptophan (5OH), 5-fluoro-DL-tryptophan (5FW), 6-fluoro-DL-tryptophan (6FW) and DL-7-azatryptophan (7AW) were first tested for the incorporation efficiency into phage particles. Fig. (8). The tryptophan auxotrophic MB5F strain was infected with fUSE5 phage carrying the

CTTHWGF TLC peptide. The infected bacteria were first cultured in a defined medium and then shifted to a medium containing the amino acid analogue to be tested. As a control, the bacteria were transferred to a medium lacking tryptophan or the analogues. After an overnight culture, the titer of the CTT-fUSE5 phage in the culture supernatant was measured by infecting the *E. coli* K91/kan. Roughly equal number of infective particles was obtained with 5FW and 6FW as compared to tryptophan. The combination of 5FW and 6FW also yielded phage particles efficiently. In contrast, the 5OH and 7AW supported the phage production poorly. Fig. (9A).

Methionine analogues ethionine and norleucine were similarly tested for the incorporation efficiency using the strain MB64F. In these experiments norleucine (Nle), but not ethionine (Eth) could be incorporated with a good efficiency. Fig. (9B). Leucine analogues norvaline (Nva) and 4-azaleucine (Ale) were also tested, as the MC1061 strain is naturally auxotrophic for leucine. However, attempts to incorporate these analogues were unsuccessful (data not shown).

The analogue incorporation efficiency could not be studied using the differential migration of tryptophan analogues in SDS-PAGE due to insufficient resolution of the major coat protein pVIII, which has only 50 amino acids and a molecular weight of about 5200. To demonstrate that the fluorinated tryptophan analogues were indeed incorporated into phage particles, we took advantage of the fact that the fluorine substitutions change the intrinsic fluorescence properties of tryptophan in proteins. Phages cultured in the presence of 5FW and 6FW were precipitated with PEG/NaCl for four times to remove any unincorporated fluorotryptophan. The resulting phages (2×10^9 phages/ml) were denatured with SDS and the fluorescence spectra recorded. The observed fluorescence emission is mainly derived from the single tryptophan in the major coat protein pVIII, which is present in about 2800 copies/virion whereas the other coat proteins are present in 2-5 copies. When the samples are excited with 295 nm wavelength, the fluorescence quantum yield of 5FW and 6FW-containing phages is highly enhanced in accordance with previous data with these analogues (Minks *et al.*, 1999). Furthermore, the emission maximum of 6FW containing phage preparation is shifted 6 nm to 345 nm, compared to the 339 nm emission maximum of the wild type phage. Fig. (10). These results indicate significant incorporation of the analogues, although quantitative analysis of the incorporation level is not possible.

To demonstrate that unnatural amino acid-containing phage libraries can be prepared and used in biopanning, we prepared CX₇C, CX₈C and X₉C libraries containing 5FW and 6FW. The libraries were obtained by infecting the MB5F strain with the wild-type CX₇C, CX₈C and X₉C libraries (Koivunen *et al.*, 1999a; Koivunen *et al.*, 2001) followed by culturing of the phage-infected bacteria in the presence of 5FW and 6FW. The amplified phage were biopanned with the KS1767 human Kaposi's sarcoma cells to isolate peptides recognizing these tumor cells, but not the endothelial cell line Eahy926. KS1767-specific peptides were obtained after subtracting the library of the peptides binding to Eahy926 cells Fig. (11). After two rounds of biopanning the enrichment was 2.2-fold, which is significant in considering the relatively slow formation of phage particles in the chemically defined medium.

Sequence Listing Free Text

15

For SEQ. ID. No. 1-4:

Description of Artificial Sequence: Oligonucleotide primer

For SEQ. ID. No. 5:

20

Description of Artificial Sequence: Oligonucleotide primer
v at positions 26, 28, 29, 31, 35 and 37 is a, c or g

For SEQ. ID. No. 6-7:

Description of Artificial Sequence: Oligonucleotide primer

25

For SEQ. ID. No. 8-11:

Description of Unknown Organism: Unknown

For SEQ. ID. No. 12-19:

30

Description of Artificial Sequence: Ala-substitution of the CTT-peptide

For SEQ. ID. No. 20:

Description of Artificial Sequence: CTT-peptide with a tryptophan analogue at position 5
Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

35

For SEQ. ID. No. 21-22:

Description of Artificial Sequence: Control sequence

For SEQ. ID. No. 23:

40

Description of Artificial Sequence: CTT-peptide with additional hydrophilic amino acids
Xaa at positions 3, 4 and 6 is any hydrophilic amino acid

For SEQ. ID. No. 24:

Description of Artificial Sequence: CTT-peptide with additional hydrophilic amino acids

References

- 5 Chong, S., Mersha, F.B., Comb, D.G., Scott, M.E., Landry, D., Vence, L.M., Perler, F.B., Benner, J., Kucera, R.B., Hirvonen, C.A., Pelletier, J.J., Paulus, H. and Xu, M.Q. (1997) Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element. *Gene*, 192: 271-81.
- 10 Dwyer, M. A.; Lu, W.; Dwyer, J. J. and Kossiakoff, A. A. (2000) *Chem. Biol.* 7, 263-274.
- Evans, T.C., Jr., Benner, J. and Xu, M.Q. (1999) The cyclization and polymerization of bacterially expressed proteins using modified self-splicing inteins. *J. Biol. Chem.*, 274: 18359-63.
- 15 Koivunen, E., Arap, W., Valtanen, H., Rainisalo, A., Medina, O.P., Heikkila, P., Kantor, C., Gahmberg, C.G., Salo, T., Kontinen, Y.T., Sorsa, T., Ruoslahti, E. and Pasqualini, R. (1999a) Tumor targeting with a selective gelatinase inhibitor. *Nat. Biotechnol.*, 17: 768-74.
- 20 Koivunen, E.; R  stel, B. H.; Rajotte, D.; Lahdenranta, J.; Hagedorn, M.; Arap, W.; Pasqualini, R. (1999b), *Methods Mol. Biol.* 129, 3-17.
- Koivunen, E.; Ranta, T. M.; Annila, A.; Taube, S.; Uppala, A.; Jokinen, M.; van Willigen, G.; Ihanus, E.; Gahmberg, C. G. J. (2001), *Cell Biol.* 153, 905-916.
- 25 Lamberg, A., Nieminen, S., Qiao, M. and Savilahti, H. (2002) Efficient insertional mutagenesis strategy for bacterial genomes involving electroporation of in vitro-assembled DNA transposition complexes of bacteriophage Mu. *Appl. Environ. Microbiol.*, 68: 705-712.
- 30 Mathys, S., Evans, T.C., Chute, I.C., Wu, H., Chong, S., Benner, J., Liu, X.Q. and Xu, M.Q. (1999) Characterization of a self-splicing mini-intein and its conversion into autocatalytic N- and C-terminal cleavage elements: facile production of protein building blocks for protein ligation. *Gene*, 231: 1-13.
- 35 Minks, C., Huber, R., Moroder, L. and Budisa, N. (1999) Atomic mutations at the single tryptophan residue of human recombinant annexin V: effects on structure, stability, and activity. *Biochemistry*, 38: 10649-59.
- 40 Mohammadi, F., Prentice, G.A. and Merrill, A.R. (2001) Protein-protein interaction using tryptophan analogues: novel spectroscopic probes for toxin-elongation factor-2 interactions. *Biochemistry*, 40: 10273-83.
- Neidhardt, F. C.; Bloch, P. L.; Smith, D. F. (1974) *J. Bacteriol.* 119, 736-747.
- 45 Paulus, H. (2000) Protein splicing and related forms of protein autoprocessing. *Annu. Rev. Biochem.*, 69: 447-96.
- 50 Ross, J.B., Szabo, A.G. and Hogue, C.W. (1997) Enhancement of protein spectra with tryptophan analogs: fluorescence spectroscopy of protein-protein and protein-nucleic acid interactions. *Methods Enzymol.*, 278: 151-90.

Tang, Y., Ghirlanda, G., Petka, W.A., Nakajima, T., DeGrado, W.F. and Tirrell, D.A. (2001) Fluorinated Coiled-Coil Proteins Prepared In Vivo Display Enhanced Thermal and Chemical Stability. *Angew. Chem. Int. Ed. Engl.*, 40: 1494-1496.

5

Williams, B. R.; Sharon, J. (2002), *Immunol. Lett.* 81, 141-148.

10

Claims

1. A method for producing a peptide having at least one disulfide bridge, comprising the steps of
 - 5 - providing a nucleic acid molecule encoding a polypeptide comprising a peptide of interest,
 - incorporating said nucleic acid molecule into an expression vector as a fusion with an intein,
 - expressing the peptide-intein-fusion, and
 - 10 - inducing the peptide cleavage by temperature and pH change.
2. The method according to claim 1, further comprising the step of
 - purifying the peptide by an affinity column.
- 15 3. The method according to claim 1, wherein the method is carried out *in vivo* in a host system.
4. The method according to claim 3, wherein the host system comprises *Escherichia coli* cells.
- 20 5. The method according to claim 1, wherein the method is carried out *in vitro*.
6. The method according to claim 1, wherein the nucleic acid molecule provided is a synthetic nucleic acid molecule, comprising a nucleotide sequence encoding a peptide of
25 interest, and elements enabling the incorporation of the nucleic acid molecule into an expression vector.
7. The method according to claim 1, wherein the nucleic acid molecule provided is a PCR-amplified nucleic acid molecule originating from a phage display vector.
- 30 8. The method according to claim 7, wherein the peptide encoded by the phage display vector contains an amino acid analogue.

9. The method according to claim 7 for preparing any peptide screened by phage display, wherein the nucleic acid molecule provided is a PCR amplicon obtained by using a pair of oligonucleotide primers flanking the nucleotide sequence encoding the peptide of interest, and containing elements required for incorporation of said sequence into an expression
5 vector.

10. The method according to claim 9, wherein the pair of oligonucleotide primers consists of a forward primer having the sequence CCT TTC TGC TCT TCC AAC GCC GAC GGG GCT, and a reverse primer having the sequence ACT TTC AAC CTG CAG TTA CCC
10 AGC GGC CCC.

11. The method according to claim 1 for constructing a library of hydrophilic peptides, wherein the nucleic acid molecule provided further comprises codons for at least one hydrophilic amino acid to be added into the peptide of interest.
15

12. The method according to claim 11, wherein the peptide GRENYHGCTTHWGFTLC is produced.

13. The method according to claim 1 for constructing a library of hydrophilic peptides, wherein the nucleic acid molecule provided further comprises codons for at least one hydrophilic amino acid for replacing an amino acid non-critical for the activity of the peptide of interest.
20

14. The method according to claim 1 for producing a pool of peptides, wherein the nucleic acid molecule provided comprises a plurality of nucleotide sequences encoding peptides of interest.
25

15. The method according to claim 14, comprising a further step of screening the peptide pool obtained for improved solubility properties.
30

16. The method according to claim 1 for producing a peptide with an unnatural amino acid, wherein the method further comprises the steps of

- providing a host cell auxotrophic for a naturally occurring amino acid to be replaced with said unnatural amino acid,

- expressing the peptide-intein-fusion in said auxotrophic host cell in the presence of an amino acid analogue.

17. The method according to claim 16, wherein the peptide CTTH(5-fluoro-W)GFTLC is
5 produced.

18. The method according to claim 16, wherein the peptide CTTH(6-fluoro-W)GFTLC is produced.

10 19. The peptide CTTH(5-fluoro-W)GFTLC having improved serum stability.

20. The peptide GRENYHGCTTHWGFTLC having improved solubility in water.

21. The peptide CTTH(5-fluoro-W)GFTLC, which is obtainable according to claim 16.
15

22. The peptide GRENYHGCTTHWGFTLC, which is obtainable according to claim 11.

23. A method for producing a peptide with an unnatural amino acid, wherein the method comprises the steps of

- 20 - expressing a library of peptides containing an amino acid analogue on a phage using an auxotrophic host,
- selecting a peptide of interest containing an amino acid analogue using phage display in an auxotrophic host,
- transferring the nucleic acid encoding said peptide into an intein vector, and
- 25 - expressing the peptide of interest according to the method of claim 16.

1/11




Figure 1A and 1B

2/11




Figure 2A, 2B, 2C and 2D

3/11



A**B**

Figure 3A and 3B

4/11




Figure 4A and 4B

5/11




Figure 5

6/11




Figure 6

7/11




Figure 7

8/11




Figure 8

9/11




Figure 9A and 9B

10/11




Figure 10

11/11




Figure 11

SEQUENCE LISTING

<110> CTT Cancer Targeting Technologies Oy

<120> Method for designing peptides

<130> 40263

<140>

<141>

<160> 24

<170> PatentIn Ver. 2.1

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 1

cctttctgct cttccaacgc cgacggggct

30

<210> 2

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 2

actttcaacc tgcagttacc cagcgccccc

30

<210> 3

<211> 59

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 3

ggtggtgctc ttccaactgt acgaccatt ggggatttac tttatgttaa ctgcaggcg 59

<210> 4

<211> 15

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 4

cgctgcagt taaca

15

<210> 5
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<220>
<221> misc_feature
<222> (26)..(37)
<223> v at positions 26, 28, 29, 31, 35 and 37 is a, c or g

<400> 5
gggtggttgct cttccaacgg cgcgcavva vtatvavggc tgtaccaccc atttacttta 60
tgttaactgc aggcg 75

<210> 6
<211> 17
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 6
atcagcggcc gcgatcc 17

<210> 7
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Oligonucleotide primer

<400> 7
ttattcggtc gaaaaggatc c 21

<210> 8
<211> 4
<212> PRT
<213> Unknown Organism

<220>
<223> Description of Unknown Organism: Unknown

<400> 8
Ala Asp Gly Ala
1

<210> 9
<211> 4
<212> PRT
<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 9

Gly Ala Ala Gly
1

<210> 10

<211> 10

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 10

Cys Thr Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 11

<211> 10

<212> PRT

<213> Unknown Organism

<220>

<223> Description of Unknown Organism: Unknown

<400> 11

Ser Thr Thr His Trp Gly Phe Thr Leu Ser
1 5 10

<210> 12

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 12

Cys Ala Thr His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 13

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 13

Cys Thr Ala His Trp Gly Phe Thr Leu Cys
1 5 10

<210> 14
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 14
Cys Thr Thr Ala Trp Gly Phe Thr Leu Cys
1 5 10

<210> 15
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 15
Cys Thr Thr His Ala Gly Phe Thr Leu Cys
1 5 10

<210> 16
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 16
Cys Thr Thr His Trp Ala Phe Thr Leu Cys
1 5 10

<210> 17
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 17
Cys Thr Thr His Trp Gly Ala Thr Leu Cys
1 5 10

<210> 18
<211> 9
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 18

Cys Thr Thr His Trp Gly Phe Ala Leu
1 5

<210> 19

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Ala-substitution of the CTT-peptide

<400> 19

Cys Thr Thr His Trp Gly Phe Ala Leu Cys
1 5 10

<210> 20

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
CTT-peptide with a tryptophan analogue at position 5

<220>

<221> SITE

<222> (5)

<223> Xaa at position 5 is 5-OH-Trp, 5-F-Trp or 6-F-Trp

<400> 20

Cys Thr Thr His Xaa Gly Phe Thr Leu Cys
1 5 10

<210> 21

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Control sequence

<400> 21

Cys Glu Arg Gly Gly Leu Glu Thr Ser Cys
1 5 10

<210> 22

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Control sequence

<400> 22

Cys Pro Cys Phe Leu Leu Gly Cys Cys

1

5

<210> 23

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<221> SITE

<222> (3)..(6)

<223> Xaa at positions 3, 4 and 6 is any hydrophilic amino acid

<220>

<223> Description of Artificial Sequence:

CTT-peptide with additional hydrophilic amino acids

<400> 23

Gly Arg Xaa Xaa Tyr Xaa Gly Cys Thr Thr His Trp Gly Phe Thr Leu

1

5

10

15

Cys

<210> 24

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:

CTT-peptide with additional hydrophilic amino acids

<400> 24

Gly Arg Glu Asn Tyr His Gly Cys Thr Thr His Trp Gly Phe Thr Leu

1

5

10

15

Cys

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00705

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C12N 15/10, C12N 15/62, C12N 15/64, C07K 7/06, C07K 7/08
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-INTERNAL, WPI-DATA, PAJ, BIOSIS, MEDLINE, REGISTRY, DGENE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	Combinatorial Chemistry & High Throughput Screening, Volume 6, 2003, Mikael Björklund et al: "Use of Intein-Directed Peptide Biosynthesis to Improve Serum Stability and Bioactivity of a Gelatinase Inhibitory Peptide", page 29 - page 35, abstract, results, table 1 --	1-9,11, 13-19;21,23
X	Gene, Volume 231, 1999, Sibylle Mathys et al: "Characterization of a self-splicing mini-intein and its conversion into autocatalytic N- and C-terminal cleavage elements: facile production of protein building blocks for protein ligation", page 1 - page 13, abstract; page 5, column 2, paragraph 2; page 8, column 2, paragraph 3 --	1-9,11, 13-16;23

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

18 December 2003

Date of mailing of the international search report

29-12-2003

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Terese Persson/Eö

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00705

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Biological Chemistry, Volume 271, no. 36, 6 September 1996, Shaorong Chong et al: "Protein Splicing Involving the <i>Saccharomyces cerevisiae</i> VMA Intein", page 22159 - page 22168, abstract; figure 4 --	1-9,11, 13-16,23
X	The Journal of Biological Chemistry, Volume 274, no. 7, 12 February 1999, Thomas C. Evans et al: "The in Vitro Ligation of Bacterially Expressed Proteins Using an Intein from <i>Methanobacterium thermoautotrophicum</i> ", page 3923 - page 3926, abstract; page 3424, column 1, paragraph 4 - column 2, paragraph 2 --	1-9,11, 13-16,23
X	The Journal of Biological Chemistry, Volume 274, no. 26, 25 June 1999, Thomas C. Evans et al: "The Cyclization and Polymerization of Bacterially Expressed Proteins Using Modified Self-splicing Inteins", page 18359 - page 18363, abstract; page 18360, column 1, paragraph 3 --	1-9,11, 13-16,23
X	Gene, Volume 192, 1997, Shaorong Chong et al: "Single-column purification of free recombinant proteins using a self-cleavable affinity tag derived from a protein splicing element", page 271 - page 281, abstract; figure 2 --	1-9,11, 13-16,23
A	WO 9947550 A1 (HELSINKI UNIVERSITY LICENSING LTD. OY), 23 Sept 1999 (23.09.99), page 6, line 20 --	15,17-22
A	WO 0036093 A2 (THE PENN STATE RESEARCH FOUNDATION), 22 June 2000 (22.06.00), abstract; page 32, line 2 - page 38, line 6; claims --	1-23

INTERNATIONAL SEARCH REPORT

International application No.

PCT/FI 03/00705

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Biochemistry, Volume 40, 2001, Fouroozan Mohammadi et al: "Protein - Protein Interaction Using Tryptophan Analogues: Novel Spectroscopic Probes for Toxin - Elongation Factor-2 Interactions", page 10273 - page 10283 --	1-23
A	Current Opinion in Biotechnology, Volume 11, 2000, Francine B Perler et al: "Protein splicing and its applications", page 377 - page 383 -- -----	1-23

INTERNATIONAL SEARCH REPORT

Information on patent family members

31/10/03

International application No.

PCT/FI 03/00705

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9947550	A1	23/09/99	AT	243709 T	15/07/03
				AU	2936599 A	11/10/99
				CA	2323239 A	23/09/99
				DE	69909076 D	00/00/00
				DK	1071704 T	20/10/03
				EP	1071704 A,B	31/01/01
				SE	1071704 T3	
				FI	980604 D	00/00/00
				JP	2002506881 T	05/03/02
				US	6624144 B	23/09/03
WO	0036093	A2	22/06/00	AU	2194800 A	03/07/00
				CA	2355934 A	22/06/00
				CN	1354788 T	19/06/02
				EP	1141250 A	10/10/01
				US	6219662 B	17/04/01